| Literature DB >> 34987871 |
Hajiba Fellah1,2, Maryam Hakkour1,2, Bouchra Delouane2, Asmae Hmamouch3, Abdelhakim Bouyahya4, Faiza Sebti2, Abderrahim Sadak1.
Abstract
Since its discovery in the 19th century, cutaneous leishmaniasis has been a major public health problem, especially with the appearance of more and more unusual cases of cutaneous lesions due to this parasite. Indeed, the present study joins the previous studies and describes a typical case of a nasal lesion due to Leishmania infection. This is a 20-year-old young man, with no particular pathological history, from an epidemic focus who presented with inflammatory nasal swelling similar to a mucocutaneous form. However, the X-ray data showed that no lysis of the bones proper to the nose was detected and no damage to the underlying mucosa was observed. Nevertheless, the parasitological diagnosis confirmed the presence of amastigotes, and the results of the molecular study showed that the electrophoretic profile was comparable to that of L. tropica. After diagnosis and confirmation, treatment with meglumine antimonate at the rate of two ampoules/injection (one ampoule = 5 ml) of antimony salt for one month was administered intramuscularly with favorable outcome. Atypical forms of cutaneous leishmaniasis constitute a rare and unusual entity often leading to diagnostic delay. For this, the clinical examination must take into account both exceptional presentations of Leishmania infection, in particular in subjects living or having stayed in an endemic area, in order to ensure appropriate and early treatment.Entities:
Year: 2021 PMID: 34987871 PMCID: PMC8723866 DOI: 10.1155/2021/3801949
Source DB: PubMed Journal: Case Rep Dermatol Med ISSN: 2090-6463
Figure 1Onset lesion of the nasal infection.
Figure 2Erythematous appearance covering the entire lobe of the nose.
Figure 3CT scan of the facial mass: no destruction of the nasal septum.
Figure 4Inflammatory nasal swelling due to Leishmania tropica.
Figure 5PCR-RFLP technique used for identification of Leishmania species (enzymatic digestion of PCR fragments by Mn1-I).
Figure 6Response of the lesion to meglumine antimoniate treatment: one week after beginning of treatment.
Figure 7Response of the lesion to meglumine antimoniate treatment: 2 weeks after beginning of treatment.
Figure 8Response of the lesion to meglumine antimoniate treatment: stopping treatment.